FTX files revised proposal to close bankruptcy and return billions to collectors: CNBC Crypto Planet

CNBC Crypto World options the latest information and everyday trading updates from the digital forex markets and offers viewers with a glance at what is ahead with higher-profile interviews, explainers, and one of a kind stories from the at any time-shifting crypto field. On modern display, Bitstamp United states CEO Bobby Zagotta, who is also the crypto exchange’s worldwide chief business officer, discusses the catalysts driving crypto’s modern rally and enforcement steps from electronic asset businesses in the United States.

Resource

World

AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed

March 27, 2026

AstraZeneca‘s stock jumped nearly 5% after Britain’s most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease (COPD) in both former smokers and in the overall population versus placebo, the company said. “This marks a notable shift […]

World

The Tech Download: How Russia could profit from Iran war helium supply chain disruption in the chip sector

March 27, 2026

This report is from this week’s The Tech Download newsletter. Like what you see? You can subscribe here. Helium has emerged as a key focus for the tech sector as industry watchers cast their minds to the implications of a prolonged Iran war. A byproduct of natural gas production, helium is crucial to semiconductor manufacturing and […]

Novartis shells out billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week

World

Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week

March 27, 2026

A sign of Swiss pharmaceutical giant Novartis is seen on the top of a building at Novartis Campus in Basel, northern Switzerland, on Sept. 9, 2025. Fabrice Coffrini | AFP | Getty Images Novartis is planning to buy U.S.-based biotech Excellergy for up to $2 billion, betting on a next-generation allergy treatment that may prove […]